Optimi Health Advances Highest-Purity Natural Psilocybin Extract to Date
Vancouver, British Columbia--(Newsfile Corp. - May 26, 2026) - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion of a production run of naturally derived psilocybin extract measuring approximately 6% psilocybin content, representing the highest-purity botanical ps
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-05-26 7:00 AM EDT | Optimi Health Corp.
Entheon Announces Termination of Business Combination Agreement with Nutravisor
Toronto, Ontario--(Newsfile Corp. - May 25, 2026) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") announces that further to its news release dated January 19, 2026, the definitive business combination agreement dated January 19, 2026, as amended on March 9, 2026 (the "Business Combination Agreement") between the Company and Nutravisor Inc. ("Nutravisor"), pursuant to which the parties had agreed to complete a business c
Biotechnology, Cannabis, Psychedelics, Cannabis Ancillary Service Provider
2026-05-25 7:21 PM EDT | Entheon Biomedical Corp.
Red Light Holland Expands New Zealand Partnership with Allu Therapeutics to Advance Access to Filament Health's GMP-Compliant PEX010 Botanical Psilocybin Drug Candidate
Toronto, Ontario--(Newsfile Corp. - May 25, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland", "Red Light", or the "Company"), is an Ontario-based organization advancing innovation and r
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2026-05-25 8:40 AM EDT | Red Light Holland Corp.
Optimi Health Announces Closing of Oversubscribed US$15 Million Public Offering
Vancouver, British Columbia--(Newsfile Corp. - May 21, 2026) - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage pharmaceutical company focused on manufacturing and distributing finished psychedelic drug products, today closed its previously announced underwritten public offering (the "Offering") in connection with the uplisting of its common shares to the Nasdaq Capital Market. The Company issued 2,400,000 common s
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-05-21 1:07 PM EDT | Optimi Health Corp.
Optimi Health Announces Pricing of Oversubscribed US$15 Million Public Offering and Nasdaq Uplisting
Vancouver, British Columbia--(Newsfile Corp. - May 20, 2026) - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical company focused on manufacturing and distributing finished psychedelic drug products, today announced the pricing of its underwritten public offering (the " Offering") in connection with the uplisting of its common shares to the Nasdaq Capital Market. The Company is offering 2,400,000 common shares at a public o
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-05-20 8:00 AM EDT | Optimi Health Corp.
Optimi Health gibt Preisfestsetzung für überzeichnetes öffentliches Angebot in Höhe von 15 Mio. US-$ und Nasdaq-Uplisting bekannt
Vancouver, British Columbia--(Newsfile Corp. - Mittwoch, 20. Mai 2026) - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) (das "Unternehmen" oder "Optimi"), ein pharmazeutisches Unternehmen im kommerziellen Stadium mit Fokus auf die Herstellung und den Vertrieb fertiger psychedelischer Arzneimittelprodukte, gab heute die Preisfestsetzung seines gezeichneten öffentlichen Angebots (das "Angebot") im Zusammenhang mit dem Uplisting seiner Stammaktien an den Nasdaq Capital Market bek
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-05-20 8:00 AM EDT | Optimi Health Corp.
Neural Portfolio Company Hanf.com Expands German Retail Footprint with New Muhldorf am Inn Store and Four Refurbished Locations
Toronto, Ontario--(Newsfile Corp. - May 19, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic solutions for mental health conditions related to substance use disorders, together with its portfolio company CWE European Holdings Inc. ("CWE"), operating as Hanf.com, one of Germany's leading CBD retailers, is pleased to announce the opening of a new Hanf.
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-05-19 7:30 AM EDT | Neural Therapeutics Inc.
Red Light Holland's Wholly Owned Subsidiary, Filament Health, Advances PEX010 Clinical Footprint with New Canadian Academic Studies in Palliative Care, Bipolar II Depression, and Healthy Adult Mechanism Research
Toronto, Ontario--(Newsfile Corp. - May 14, 2026) - Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) (FSE: 4YX) ("Red Light" or the "Company") is an Ontario based organization advancing innovation and research within the legal psychedelic sector. Following its acquisition of Filament Health Corp. ("Filament"), the Company has expanded its pharmaceutical grade manufacturing, regulatory, and clinical research capabilities, supporting the advancement of naturally derived psilocybin development
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2026-05-14 8:30 AM EDT | Red Light Holland Corp.
Red Light Holland Announces Shareholder Approval of Name Change and Announces Voting Results from 2026 Annual General and Special Meeting of Shareholders
Toronto, Ontario--(Newsfile Corp. - May 13, 2026) - Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) (FSE: 4YX) ("Red Light Holland" or the "Company") is pleased to announce that shareholders overwhelmingly approved the Company's proposed corporate name change at the Company's annual general and special meeting of shareholders ("Shareholders") held on Monday, May 11, 2026 at the Company's office in Toronto (the "Meeting"). The special resolution approving t
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2026-05-13 9:12 AM EDT | Red Light Holland Corp.
PharmaDrug Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus
Toronto, Ontario--(Newsfile Corp. - May 13, 2026) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of natural medicines is is pleased to announce that Sairiyo Therapeutics Inc. ("Sairiyo"), a company 51% owned by PharmaDrug and 49% owned by PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher"), is pursuing its strategic plans to focus on the clinical devel
Biotechnology, Cannabis, Psychedelics, Cannabis Manufacturer
2026-05-13 8:50 AM EDT | PharmaDrug Inc.
Red Light Holland Highlights Publication of Randomized Clinical Trial Showing a Single Dose of Psilocybin Reduced Cocaine Use, with Filament Health Holding the Exclusive License to the Data and Intellectual Property
Peer-reviewed results published yesterday (May 7, 2026) in JAMA Network Open demonstrate that a single dose of psilocybin meaningfully reduced cocaine use in adults with cocaine use disorder over six months, with no serious adverse events Filament Health Corp., a wholly-owned subsidiary of Red Light Holland, holds the exclusive worldwide license to the trial data and certain associated intellectual property, with the goal of supporting future regulatory authoriza
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2026-05-08 7:30 AM EDT | Red Light Holland Corp.
Red Light Holland's Wholly Owned Subsidiary, Filament Health, Expands Distribution of PEX010 Across Canadian and U.S. Research Institutions
Toronto, Ontario--(Newsfile Corp. - May 7, 2026) - Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) (FSE: 4YX) ("Red Light" or the "Company") is an Ontario-based organization advancing innovation and research within the legal psychedelic sector. Following its acquisition of Filament Health Corp. ("Filament"), the Company has expanded its pharmaceutical-grade manufacturing, regulatory, and clinical research capabilities, supporting the advancement of naturally derived psilocybin development
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2026-05-07 7:30 AM EDT | Red Light Holland Corp.
Red Light Holland Announces Intention to Rebrand
New name and branding to be announced in the coming weeks, better aligned with the Company's scientific mandate and all business segments Name change resolution to be voted on by shareholders at the upcoming Annual General and Special Meeting ("AGSM") on May 11, 2026 Company urges all shareholders to vote IN FAVOUR of the name change resolution to support the rebranding exercise Rebranding reflects the combined focus on clinical research, GMP
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2026-05-04 8:30 AM EDT | Red Light Holland Corp.
Adaptogenics Health Corp. Announces Strategic Review of Health & Wellness Opportunities and Management Changes
Vancouver, British Columbia--(Newsfile Corp. - May 1, 2026) - Adaptogenics Health Corp. (CSE: ADPT) ("Adaptogenics", the "Company") announces that its board of directors has initiated a strategic review to evaluate potential business opportunities within the broader health and wellness sector. As part of this review, the Company's board of directors and senior management are examining a range of potential strategic initiatives, which may include prospective b
Household / Consumer / Cosmetics, Psychedelics
2026-05-01 2:40 PM EDT | Adaptogenics Health Corp.
Neural Therapeutics Announces Filing and Mailing of Meeting Materials for Annual and Special Meeting to Approve Series B Transactions with CWE
Toronto, Ontario--(Newsfile Corp. - May 1, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic solutions for mental health conditions related to substance use disorders, announces that it has filed on SEDAR+ and completed the mailing of its notice of annual and special meeting, management information circular and related meeting materials (collectively, the "Mee
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-05-01 8:04 AM EDT | Neural Therapeutics Inc.
Red Light Holland Completes Acquisition of Filament Health, Creating a Global Leader in Psychedelic Drug Development, Commercialization and Distribution
Establishes a vertically integrated platform spanning pharmaceutical-grade botanical drug development and global consumer distribution Adds Filament's extensive intellectual property portfolio, including 70+ patents and proprietary extraction technologies Leverages Health Canada Dealer's License and FDA-aligned clinical development pathways, including IND-enabled activities Positions the Company at the forefront of the rapidly emerging regu
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2026-04-30 7:30 AM EDT | Red Light Holland Corp.
Red Light Holland Announces Filament Health Obtains Final Order for Proposed Arrangement
Toronto, Ontario--(Newsfile Corp. - April 29, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light" or the "Company") and Filament Health Corp. (OTC: FLHLF) ("Filament") are pleased to announce that, further to their joint press release dated March 10, 2026, March 23, 2026 and April 27, 2026, that the Supreme Court of British Columbia has issued a final order (the "Final Order") approving the previously announced acquisition by Red Ligh
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2026-04-29 7:30 AM EDT | Red Light Holland Corp.
Red Light Holland Announces Filament Health Shareholder Approval of Acquisition
Toronto, Ontario--(Newsfile Corp. - April 27, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light") and Filament Health Corp. (OTC: FLHLF) ("Filament") are pleased to announce that, further to their joint press release dated March 10, 2026 and March 23, 2026, Filament's shareholders (the "Filament Shareholders") have approved each of the matters voted on at the Filament annual general and special meeting ("Filament Meeting") hel
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2026-04-27 7:30 AM EDT | Red Light Holland Corp.
Red Light Holland Showcases Growing Clinical Demand for Filament Health's PEX010 with New and Repeat University Shipments
Toronto, Ontario--(Newsfile Corp. - April 24, 2026) - Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) (FSE: 4YX) ("Red Light" or the "Company") is pleased to highlight continued expansion and execution of clinical supply shipments of PEX010, a botanical psilocybin drug candidate developed by Filament Health Corp., to leading Canadian research institutions. Following its press release dated April 7, 2026, Red Light is highlighting recent accomplishments and ongoing momentum, including
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2026-04-24 8:26 AM EDT | Red Light Holland Corp.
Psyched Wellness Highlights U.S. Federal Policy Momentum Supporting Psychedelic Sector
Toronto, Ontario--(Newsfile Corp. - April 23, 2026) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company"), a life sciences company focused on the production and distribution of Amanita Muscaria-derived health and wellness products, today highlights recent U.S. federal policy developments supporting psychedelic research and outlines the potential implications for the sector and the Company. Recent announcements by U.S. President Donald Trump include an exec
Cannabis, Health, Psychedelics, Cannabis Manufacturer
2026-04-23 7:30 AM EDT | Psyched Wellness Ltd.